{'fraction_non_alphanumeric': 0.020743301642178046, 'fraction_numerical': 0.014693171996542784, 'mean_word_length': 5.5423728813559325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Review of the antiviral activity and pharmacology of monoglycerides and implications for treatment of COVID-19

Monoglycerides are a class of lipids derived from fatty acids with well established antiviral properties. Monoglycerides are widely used in food processing, cosmetics and in nutritional supplements. This review examines the biochemical and pharmacological properties of monoglycerides and fatty acids as they pertain to COVID-19 pathogenesis. Information on monoglycerides, fatty acids and COVID-19 is presented with sources gathered through PubMed, Elsevier, JSTOR, Oxford University Press Medicine Archive, Wiley, MedRxiv and Google. The antiviral activity of monoglycerides has been documented since the 1970's. In vitro studies have shown that viral concentrations of enveloped viruses were reduced by over 10,000 fold in the presence of monoglycerides such as glycerol monolaurate. Moreover, glycerol monolaurate is widely available and generally recognized as safe (GRAS) by the FDA. The aim of this review is to present an evidence based case for further investigation into this class of compounds for the potential treatment of COVID-19.